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Introduction: Cross-sectional studies have identified long chain omega-3 polyunsaturated
fatty acids (eicosapentaenoic acid 20:5n-3 and docosahexaenoic acid 22:6n-3 (O3PUFA) in
association with fewer white matter lesions and better executive function in older adults.
We hypothesized that O3PUFA are associated with less executive decline over time and
that total white matter hyperintensity volume (WMH) mediates this association.
Methods: Eighty-six non-demented older adults were followed over 4 years after
measurement of plasma O3PUFA with annual evaluations of cognitive function. A subset
of these participants also had brain MRI of total WMH available to conduct a formal
mediation analysis of a putative relationship between O3PUFA and cognitive function.
Results: Mean age at baseline was 86, 62% were female and 11% carried the APOE4
allele. Each 100μg/ml increase in plasma O3PUFA associated with 4 s less change in
executive decline per year of aging (p = 0.02, fully adjusted model). O3PUFA was not
associated with verbal memory or global cognitive changes. The significance of the
association between O3PUFA and better executive function was lost once WMH was
added to the regression model.
Conclusion: Executive decline with age appears to be a cognitive domain particularly
sensitive to plasma O3PUFA in longitudinal examination. O3PUFAmay modulate executive
functioning by mechanisms underlying the development of WMH, a biologically plausible
hypothesis that warrants further investigation.
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INTRODUCTION
Delaying the onset of Alzheimer’s disease and other late life
dementias is an agenda budding across the globe. Characterizing
the heterogeneity in structural and functional brain changes that
relate to dementia risk will enable preventive therapies to target
these characteristics in populations primed to gain benefit. Diet
and nutrition pose a significant opportunity for prevention; how-
ever, success here also requires knowledge of the risk profile in
order to engage appropriately.
Cerebral white matter hyperintensities (WMH), largely con-
sidered a marker of small vessel disease and dementia risk, are
of significant interest to prevention strategies (Schmidt et al.,
2003; Garde et al., 2005; Bastos Leite et al., 2006; Kramer et al.,
2007; Silbert et al., 2008; Debette et al., 2010; Gorelick et al.,
2011). These WMH are prevalent in 60–92% of non-demented
elders age 65 and older and increase risk for cognitive impairment
(de Leeuw et al., 2001; Silbert et al., 2009). WMH represents an
early structural MRI risk factor for Mild Cognitive Impairment
and dementia (Silbert et al., 2012), and thus, provides an attrac-
tive therapeutic target. The design of rational therapy for this
early brain structural change requires knowledge of its patho-
physiology. Both intake (Virtanen et al., 2008) and peripheral
concentration of long chain omega-3 polyunsaturated fatty acids
(O3PUFA) are associated with less WMH in cross–sectional
studies (Bowman et al., 2012; Tan et al., 2012; Virtanen et al.,
2013). Although the cognitive consequences associated with
WMH accumulation may ultimately pervade several domains,
executive dysfunction with impaired information processing and
cognitive flexibility have been noted as early indicators of its
accrual (Schmidt et al., 1993; DeCarli et al., 1995; Adak et al.,
2004; Brickman et al., 2006; Verdelho et al., 2007). Intrigued by
this fabric of literature, we tested the hypothesis that O3PUFA
associates with less executive decline, and that WMH mediates
the relationship between these fatty acids and executive function.
MATERIALS AND METHODS
STUDY POPULATION
The Oregon Brain Aging Study (OBAS) is a cohort study of brain
aging in people age 65 and older free of usual confounding fac-
tors known at the time to modify the risk for cognitive decline
(i.e., vascular disease, smoking, stroke, diabetes) (Kaye et al.,
1994). Enrollment was opened in 2004 to also include volun-
teers with stable chronic conditions common with advanced age
(i.e., hypertension, diabetes) to better represent the general pop-
ulation. Clinical, neuropsychometric and brain MRI are collected
annually. Clinical Dementia Rating (CDR) (Morris, 1993) scale is
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based on interviews with the participant and their collateral his-
torian about functioning and cognitive skills in conjunction with
theMMSE (Folstein et al., 1975) and the Cognistat (Kiernan et al.,
1987). Blood was collected appropriately for nutrient biomarkers
beginning in the 2006–2007. Inclusion was restricted to non-
demented participants (CDR ≤ 0.5). Eighty-six participants had
plasma fatty acids and psychometric measures available for longi-
tudinal analysis. Thirty-two of these 86 also had MRI collected at
the time of the nutrient blood draw to permit a formal mediation
analysis.
STANDARD PROTOCOL APPROVAL AND PATIENT CONSENT
Informed consent was obtained from all subjects for partici-
pation in this study, which was approved by the institutional
review board for human study at Oregon Health & Science
University.
BIOMARKER ACQUISITION AND ANALYSIS
Plasma long-chain omega-3 fatty acids
Fasting blood was collected between the hours of 0700 and
1200 noon Pacific Standard Time beginning in September
of 2006 and ending December 2007. Total lipid long chain
n-3 polyunsaturated fatty acids as methyl esters were quan-
tified using gas chromatography equipped with flame ioniza-
tion detector and expressed as absolute plasma concentrations
(μg/mL)(Bowman et al., 2012). Plasma eicosapentaenoic acid
(20:5n-3) and docosahexaenoic acid (22:6n-3) were combined
(O3PUFA).
Volumetric brain MRI
Brain regions of interest were obtained using MRI 1.5 T mag-
net and REGION image analysis software. The procedures have
been previously described (Mueller et al., 1998). Briefly, the
sums of pixel areas for all slices were converted to volumet-
ric measures by multiplying by the slice thickness for each of
the following regions of interest: total white matter hyperinten-
sity volume (WMH includes periventricular and subcortical deep
signals) and supratentorial brain volume as total cerebral brain
volume (TBV, excluding cerebellum and brain stem). Regression
for brain tissue, CSF, and WMH collectively against bone cre-
ates a boundary along the inner table of the skull to determine
the total intracranial volume. Additional boundaries were manu-
ally traced along the tentorium cerebelli and the superior border
of the superior colliculus, the pons, and the fourth ventricle.
The pituitary, vessels in the sphenoid region, and any sinuses
that may have been included by the automatic regression were
excluded manually. Using REGION’s sampling tools, the ana-
lyst selects representative, unambiguous pixels of WMH (as well
as brain tissue, fluid, and bone) from the multi-echo sequence
display. Proton and T2 intensities are included in a regression
model taking into account the location of each pixel that differ-
entiates the tissue types. Distinction of WMH from brain tissue
and fluid is achieved by visualizing higher signal intensities on
proton density and T2 images. Inter-rater reliability coefficients
using this approach for white matter segmentation are 0.85 and
>0.95 for total intracranial, brain, and ventricular regions of
interest.
PRIMARY OUTCOMES AND POTENTIAL CONFOUNDERS
Neuropsychometrics
Previous cross-sectional analysis (Bowman et al., 2012)
demonstrated O3PUFA in association with Trail Making
Test Part B (Reitan, 1958), a measure commonly utilized to reflect
executive function. This test was therefore used as our primary
outcome measure for the current longitudinal analysis. WMS-R
Logical Memory Story delayed (Wechsler, 1981) and the MMSE
were also analyzed to resolve cognitive measures with apparent
sensitivity to O3PUFA over time.
Potential confounders and other covariates
We utilized a parsimonious approach to our model building by
including potential confounders on the basis of their previous
association with cognitive decline. These included age (con-
tinuous), gender (man/women), education (continuous, years),
APOE genotype determined using PCR (e4 carrier, y/n), hyper-
tension (y/n), and depression (y/n). We restricted our covariates
entered into the mediation analysis on the basis of their signifi-
cant association with our outcomes of interest to avoid depleting
degrees of freedom in a limited sample size (Supplementary
Material, age and APOE4 carrier status, total intracranial vol-
ume). Covariates were collected and confirmed during the clinical
interview (i.e., hypertension, depression).
STATISTICAL ANALYSIS
All statistics were performed in STATA v10.1 software (College
Station, TX). Baseline differences in characteristics between those
with and without MRI were calculated using independent t-test
or Wilcoxon rank sum test for continuous variables and Pearson’s
chi-square test or Fisher’s exact test for categorical variables as
appropriate.
Longitudinal analysis
Linear mixed effects models estimated the mean and within-
person slope of cognitive change by baseline plasma O3PUFA
concentration. The mixed effects model accounts for the within-
person correlations on repeated measures. The interaction term
(O3PUFA x Age) represents the “effects” of the baseline O3PUFA
on cognitive change over time (using age at visit as the time
variable). We interpret this as the annual cognitive change per
unit increase in baseline O3PUFA. In addition to considering
O3PUFA as a continuous measure, we also examined the dif-
ference between O3PUFA 1-SD above the mean (>100μg/ml)
versus a lesser value in relation to cognitive change. O3PUFA
dichotomized (>100μg/ml or less) in this setting represents the
between-group annual difference in slope of cognitive change
(high vs. low).
Formal mediation analysis
This procedure was utilized in an attempt to better describe
the role of O3PUFA in relation to WMH and cognitive func-
tion. Differences between participants with and without MRI
are presented in Table 1. Our mediation analysis used the
baseline data and a 3-step framework (Baron and Kenny,
1986). The first step attempts to reproduce the initial model
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Table 1 | Baseline characteristics of the study popualtiona.
n = 86 MRI available P for differenceb
No (n = 54) Yes (n = 32)
Age, y 85.7 (10) 81.7 (11.0) 92.4 (3.5) <0.0001
Female, n (%) 53 (62) 28 (52) 25 (78) 0.02
Years of education 15 (3) 15.3 (2.6) 14.5 (2.4) 0.12
APOE4 carrier, n (%) 9 (11) 8 (15) 1 (3) 0.14
Hypertension, n (%) 36 (42) 20 (38) 16 (50) 0.27
Depression, n (%) 15 (17) 10 (19) 5 (16) 0.73
CDR of 0, n (%) 60 (70) 38 (70) 22 (69) 0.87
PLASMA NUTRIENTS
EPA (20:5n-3), μg/ml 16.5 (10.5) 16.9 (12.4) 15.8 (7.8) 0.66
DHA (22:6n-3), μg/ml 68.1 (17.8) 67.1 (17.9) 69.6 (17.6) 0.48
O3PUFA (EPA+DHA) 84.5 (26.7) 84.1 (28.1) 85.4 (24.6) 0.61
Vitamin B12, pg/ml 659 (312) 666 (306) 646 (328) 0.73
PSYCHOMETRICS
MMSE 28 (2) 28.2 (1.9) 27.5 (2.2) 0.17
Trails B 137 (77) 123 (73) 160 (79) 0.01
Paragraph recall 14.0 (4.7) 15.0 (3.8) 12.3 (5.6) 0.02
VOLUMETRIC MRI, cc
Intracranial – – 1107.5 (106.4) –
Brain – – 821.1 (84.7) –
Ventricular – – 55.2 (16.5) –
WMH – – 13.8 (8.8) –
aMean and standard deviation unless otherwise stated.
bBaseline differences between those with and without MRI calculated by independent t-test or Wilcoxon rank sum test for continuous variables and Pearson’s
chi-square or Fisher’s exact test for categorical variables as appropriate.
APOE4, Apolipoprotein E epsilon 4 allele carrier; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; Trails B, Trail Making Test – Part B; Paragraph recall,
Wechsler memory scale revised; WMH, total white matter hyperintensity.
that demonstrates the association between O3PUFA and cog-
nitive function. In the second step, we examine the asso-
ciation between the proposed “mediator” (i.e., WMH) and
cognitive function and O3PUFA with the mediator WMH.
The third step includes O3PUFA and WMH as simulta-
neous predictors of cognitive function. Attenuation of the
beta-coefficient >10% or loss of statistical significance (alpha
level>0.05) was stated a priori to imply a mediation effect in
this construct. These regression models were adjusted for vari-
ables that demonstrated a significant association with cognitive
function in the study sample (alpha value <0.05, two-sided)
(Supplementary Material).
RESULTS
Sixty-two percent of the participants were female and the mean
age at baseline was 86. Prevalence of APOE4 allele carrier status
was 11% (Table 1). The mean MMSE was 28. Forty-two per-
cent were being treated for hypertension and 17% for depression.
Vitamin B12 deficiency was prevalent in 4%. Mean duration of
follow-up was 3.9 years (range 1–5) (Table 1). Annual change in
Trail Making Test Part B (Trails B) as measured by speed in test
performance was 3.5 (± 0.42) s, −0.2 (± 0.04) points onWMS-R
Delayed Paragraph Recall, and −0.1 (±0.02) points on MMSE.
In the results that follow, all subjects are included in the eval-
uation of relationships between O3PUFA and cognitive change
(n = 86), while only those with MRI are included in the medi-
ation analysis (n = 32). The participants with MRI were older
and predominantly female in comparison to those without MRI
(Table 1).
PLASMA O3PUFA AND COGNITIVE DECLINE (TABLE 2)
Plasma O3PUFA (EPA+DHA) was associated with less execu-
tive decline (Trails B) after adjustment for age, gender, education,
APOE4, hypertension, and depression (p = 0.02) (Table 2). The
magnitude of the association can be interpreted as a 4 s less
decline on Trails B per year for each 100μg/ml increase in plasma
O3PUFA. These estimates indicate that an individual with an
O3PUFA concentration of 200μg/ml might be expected to com-
plete the Trails B task 4 s faster than an individual with an
O3PUFA of 100μg/ml per year of aging. Given that each year
of aging in our population was associated with a mean increase
in Trails B completion time of approximately 4 s over the dura-
tion of follow up, these estimates indicate a 1 year delay in
age-dependent executive decline per 100μg/ml baseline O3PUFA
concentration. By contrast, decline in Paragraph Recall (p =
0.83) and MMSE (p = 0.21) had no apparent relationship with
O3PUFA.
Figure 1 illustrates the deceleration in trajectory of executive
decline in people with “high” plasma O3PUFA versus people
below this threshold.
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Table 2 | Plasma O3PUFA and cognitive decline in older adults over 4-years (n = 86)a.
Trail B Paragraph recall MMSE
β SE P β SE P β SE P
O3PUFA × Age −0.04 0.02 0.02 0.00 0.00 0.83 0.00 0.00 0.21
O3PUFA baseline −0.66 0.27 0.02 0.01 0.02 0.56 0.01 0.01 0.19
Age 6.66 1.53 0.00 −0.19 0.11 0.10 −0.19 0.05 0.00
Gender 14.61 10.81 0.18 1.56 0.83 0.06 −0.05 0.22 0.81
Education −1.37 2.74 0.62 0.17 0.18 0.36 −0.01 0.07 0.88
APOE4 15.19 13.99 0.28 0.09 1.17 0.94 −0.34 0.31 0.28
Hypertension 14.43 11.05 0.19 −0.51 0.83 0.54 −0.50 0.26 0.06
Depression 11.44 14.28 0.42 0.95 1.09 0.38 0.05 0.34 0.88
aLinear mixed effects model; age used as the time variable; O3PUFA at baseline includes plasma EPA+DHA; APOE4, apolipoprotein E epsilon 4 carrier; Gender,
female; Education years; hypertension and depression require current treatment to qualify.
FIGURE 1 | Predicted within-person(circles) and mean trajectory (lines)
of executive decline for subjects with plasma O3PUFA concentration
above 110 μg/ml (dark circles, solidline) or below this threshold(open
circles, dashed line) at base line (n = 86). Coefficient estimates
calculated in the linear mixed effects model were used to predict
trajectories. Participants with O3PUFA ≤110μg/ml (open circles and line)
had an accelerated rate of executive decline by 2.7 s per year (β = 2.7; 95%
confidence interval −5.11 to −0.22; age, gender, education, APOE4, hyper
tension, depression adjusted).
PLASMA O3PUFA ANDWMHMEDIATED EXECUTIVE FUNCTION
(FIGURE 2)
O3PUFA associated with less WMH (β = −0.188, p = 0.007,
Figure 2A) where O3PUFA explained 28.5% of the variance in
totalWMH (Figure 3).WMHburden associated with worse exec-
utive function (Trials B, β = 4557.87, p = 0.005, Figure 2B).
O3PUFA associated with better executive function (Tails B,
β = −1.15, p = 0.025, Figure 2C), however, after adding WMH
as a “mediating” variable into the regression equation that
included O3PUFA, age, APOE4 and total intracranial volume
simultaneously as predictors of executive function, the significant
association between O3PUFA and better executive function was
lost (β = 0.54, p = 0.332, Figure 2D) and the WMH associa-
tion with executive dysfunction remained marginally significant
(β = 3589.95, p = 0.056, not illustrated in the Figure).
DISCUSSION
This longitudinal study of older adults at risk for dementia and
followed over 4 years found significantly less executive decline
in those with higher plasma O3PUFA at baseline. The calcu-
lated estimate indicates a 1-year delay in age-dependent executive
decline per 100μg/ml increase in plasma O3PUFA at baseline.
We also found that plasma O3PUFA above 110μg/ml associated
with more stable executive function over time, which proposes
one attainable threshold for neuroprotection. O3PUFA was not
associated with verbal memory and MMSE. This implies that
O3PUFA effects are more isolated to skills of executive function
early on in people at risk for dementia. The mediation anal-
ysis further supports this notion since WMH accumulation is
known to impact executive function and we demonstrate WMH
mediation of the relationship between O3PUFA and executive
dysfunction. Together, this evidence underlines important struc-
tural and functional brain parameters that seem well suited for
targeting with O3PUFA therapy.
Delayed and logical verbal memory and MMSE changes
were not associated with O3PUFA. However, executive decline
appeared sensitive to O3PUFA. The mediation analysis is consis-
tent with other literature indicating that prefrontal cortical execu-
tive skills are affected early during WMH accumulation (Schmidt
et al., 1993; DeCarli et al., 1995; Adak et al., 2004; Brickman et al.,
2006; Verdelho et al., 2007; Barbey et al., 2012). O3PUFA has
pleiotropic effects that might explain this relationship, including
effects on cerebral blood flow (Jackson et al., 2012), endothe-
lial cell health (Yang et al., 2012), structural integrity of myelin
(Pu et al., 2013), and preservation of neuronal energy with aging
(Kuczynski et al., 2010).
Two other epidemiological studies have examined the rela-
tionship between O3PUFA and cognitive decline. Beydoun et al.
(2007) were also unable to appreciate a relationship with global
cognitive decline in the Atherosclerosis Risk in Communities
Study. However, they did find O3PUFA associated with less
decline in verbal/categorical fluency tasks which reflect executive
control; requiring people to organize concepts in a novel way (i.e.,
naming words beginning with a particular letter or category with
time constraints). They also report a more robust relationship in
people with hypertension and dyslipidemia, two morbidities also
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FIGURE 2 | O3PUFA and white matter mediated executive function in
older adults (n = 32). All models adjusted for age and APOE4, and
models with WMH also adjusted for total intracranial volume. (A) Higher
O3PUFA and less white matter hyper-intensities (WMH) highlighted in
green (subcortical deep) and blue (periventricular). (B) Higher WMH and
worse executive function (prolonged completion time for Trail B test). (C)
Higher O3PUFA and better executive function (shorter completion time
for Trail B test). (D) Association between O3PUFA and better executive
function is lost once WMH is added to the regression model (P = 0.332)
representing mediation.
FIGURE 3 | Plasma O3PUFA explains 28.5% of the total variance in
WMH in non-demented older adults (n = 32).
sensitive to O3PUFA (Mozaffarian and Wu, 2011). Samieri et al.
(2011) did not observe a relationship between O3PUFA (DHA or
EPA) and MMSE change over 7 years in a Bordeaux subset of the
3 City study or an association with executive decline represented
by Trails B. This inconsistency with our results in OBAS may
be attributed to several factors, including differences in O3PUFA
measures themselves (EPA and DHA as a relative percentage of
total fatty acids versus an absolute concentration that appears
more informative in our OBAS sample that has both), the age
of the cohort (mean age 74 vs. 86 in OBAS), slower annual rates
of executive decline (about 1 s/year decline in Trails B vs. 4 s/year
in OBAS), and the potential for lower WMH prevalence in the
Bordeaux sample compared with OBAS.
Several clinical trials to prevent age-related cognitive decline
in the cognitively intact using O3PUFA therapy have been com-
pleted (van de Rest et al., 2008; Dangour et al., 2010; Geleijnse
et al., 2012) and others are underway (Danthiir et al., 2011).
Each completed trial has been unsuccessful, however, the current
study results suggest that the design of the clinical trials them-
selves may explain the null effect. For example, one trial enrolled
non-demented subjects age 66–74 and followed subjects for only
6months and executive function was examined (van de Rest et al.,
2008). Another trial included secondary outcomes of executive
function (e.g., digit span backwards and animal naming), but
Trails B itself was not administered, and the population was at
low vascular risk, younger age, and follow-up duration was lim-
ited at 2 years (Dangour et al., 2010). Geleijnse et al trial did
examine a population with vascular risk (Geleijnse et al., 2012),
but employed the MMSE as the primary outcome, which now
has consistently shown to be insensitive to O3PUFA in obser-
vational and experimental studies of older adults at risk for
dementia.
There were limitations in our study. We have plasma O3PUFA
measurements available from a single time point in each par-
ticipant, and we assume that this is a reasonable representation
of long-term O3PUFA status, the type of nutritional exposure
most inherently significant to brain aging. Our sample size is
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smaller than studies of cognitive aging and incident dementia
using subjective measures of dietary intake (i.e., food frequency
questionnaire). However, studies using self-report are susceptible
to measurement error that we circumvent by utilizing quanti-
tative nutrient biomarkers (Bowman et al., 2011; Tangney and
Scarmeas, 2012). These permits more power, and, in turn a more
conservative sample size to identify important relationships.
In conclusion, these results add longitudinal data to a lim-
ited body of literature that further indicate WMH and executive
function as features of cognitive aging that appear sensitive to
O3PUFA early in the evolution of cognitive decline. The hypoth-
esis that O3PUFA can prevent vascular cognitive aging warrants
further study.
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